Evidence map›Paper›PMID 30340368›Full record

ArticleMolecules (Basel, Switzerland)2018

Design of a New α-1-

Izumi Nakagome, Atsushi Kato, Noriyuki Yamaotsu, Tomoki Yoshida, Shin-Ichiro Ozawa, Isao Adachi, Shuichi Hirono

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Izumi NakagomeSchool of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan. nakagomei@pharm.kitasato-u.ac.jp.
Atsushi KatoDepartment of Hospital Pharmacy, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. kato@med.u-toyama.ac.jp.
Noriyuki YamaotsuSchool of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan. yamaotsun@pharm.kitasato-u.ac.jp.ORCID 0000-0002-4302-1085
Tomoki YoshidaSchool of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan. yoshidat@pharm.kitasato-u.ac.jp.
Shin-Ichiro OzawaSchool of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan. ozawas@pharm.kitasato-u.ac.jp.
Isao AdachiDepartment of Hospital Pharmacy, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. adachi@med.u-toyama.ac.jp.
Shuichi HironoSchool of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan. hironos@pharm.kitasato-u.ac.jp.
Kitasato University · JPToyama University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some point mutations in β-glucocerebrosidase cause either improper folding or instability of this protein, resulting in Gaucher disease. Pharmacological chaperones bind to the mutant enzyme and stabilize this enzyme; thus, pharmacological chaperone therapy was proposed as a potential treatment for Gaucher disease. The binding affinities of α-1-

Indexed as

Binding SitesEnzyme StabilityGaucher DiseaseGlucosylceramidaseHumansImino SugarsLigandsMolecular ChaperonesMolecular Docking SimulationMolecular Dynamics SimulationMutant ProteinsPoint MutationProtein BindingSugar AlcoholsarabitolGlucosylceramidaseImino SugarsLigandsMolecular ChaperonesMutant ProteinsSugar Alcoholsdrug designGaucher diseaseligand dockingmolecular dynamicspharmacological chaperone

Identifiers

PMID30340368
PMCPMC6222826
OpenAlexW2896923242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.